Histamine glutarimide

Histamine glutarimide
Clinical data
Other namesXC-8
Legal status
Legal status
  • Investigational
Identifiers
  • 1-[2-(1H-imidazol-5-yl)ethyl]piperidine-2,6-dione
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
Chemical and physical data
FormulaC10H13N3O2
Molar mass207.233 g·mol−1
3D model (JSmol)
  • C1CC(=O)N(C(=O)C1)CCC2=CN=CN2
  • InChI=1S/C10H13N3O2/c14-9-2-1-3-10(15)13(9)5-4-8-6-11-7-12-8/h6-7H,1-5H2,(H,11,12)
  • Key:DYKZYSKWOHKZMF-UHFFFAOYSA-N

Histamine glutarimide is an investigational new drug that is being evaluated for the treatment of cough in acute respiratory infection.[1][2] It is a glutaminyl cyclase inhibitor.[3]

References

  1. ^ "Histamine glutarimide - EURRUS Biotech". AdisInsight. Springer Nature Switzerland AG.
  2. ^ Clinical trial number NCT05273619 for "Efficacy and Safety of XC8, Film-coated Tablets, 40 mg in Patients With Dry Non-productive Cough Against Acute Respiratory Viral Infection" at ClinicalTrials.gov
  3. ^ Romanova J, Chikina E, Rydlovskaya A, Pohl W, Renner A, Zeifman A, et al. (December 2020). "New Anti-Chemokine Oral Drug XC8 in the Treatment of Asthma Patients with Poor Response to Corticosteroids: Results of a Phase 2A Randomized Controlled Clinical Trial". Pulmonary Therapy. 6 (2): 351–369. doi:10.1007/s41030-020-00134-5. PMC 7671956. PMID 33095411.


This article is issued from Wikipedia. The text is available under Creative Commons Attribution-Share Alike 4.0 unless otherwise noted. Additional terms may apply for the media files.